Vytrus Biotech, the company specialized in active ingredients derived from plant biotechnology for skin and hair care, presents its latest innovation at in-cosmetics Korea 2026: Toleroxyl™ – Re-educating urban skin.
Vytrus introduces the first cosmetic active designed as a Tolerogen (a new cosmetic category) to help the skin’s immune system generate tolerance, rather than simply suppressing visible signs of reactivity.
Toleroxyl™ is a new active ingredient developed through Vytrus’ biotechnology platforms. Inspired by the skin’s own biological signals, it targets Langerhans cells (LC), the immune decision-makers of the epidermis, to help restore immune tolerance, comfort and visible resilience in urban skin exposed to continuous environmental and indoor stressors.
The innovation will be officially presented at in-cosmetics Korea 2026, where Vytrus Biotech will introduce the concept of immune re-education in cosmetics and the paradigm shift represented by this new active: moving beyond soothing, anti-pollution and anti-inflammatory approaches toward skin tolerance and immune recalibration.
Sensitive skin: a growing category still looking for new answers
Sensitive skin has become one of the fastest-growing consumer concerns worldwide. Modern lifestyles, indoor environments and continuous low-grade exposure to pollutants are contributing to an increase in redness, tightness, burning, stinging and discomfort. Consumers often describe skin that “overreacts to everything” or “never stays calm for long”, reflecting a deeper biological issue: the skin has not necessarily become weaker, but it may have lost its ability to distinguish harmless urban stressors from real threats.
Until now, most sensitive skin solutions have focused on immediate relief: soothing, calming, blocking or reducing visible symptoms. However, these approaches may leave the underlying immune miscalibration untouched. With Toleroxyl™, Vytrus proposes a new cosmetic logic: train the skin, do not just silence it.
Introducing the Tolerogen: a new cosmetic category
The new active opens this new category (a Tolerogen) under the vision of training the skin’s immune system to generate tolerance. Instead of suppressing inflammation, it educates immune cells to stop overreacting to harmless stimuli.
Toleroxyl™ has been developed to address this biological challenge through a highly precise mechanism based on GM-CSF, a human protein involved in the differentiation, survival and functional programming of Langerhans cells. These cells play a crucial role in deciding whether the skin responds with inflammation or tolerance.
Produced using plants as biofactories, Toleroxyl™ is designed from a human signal and grown through a sustainable plant-based recombinant protein platform. This enables molecular precision, correct protein folding and a clean, scalable production system, aligning advanced biotechnology with the cosmetic industry’s demand for high-performance and sustainable active ingredients.
Re-educating Langerhans cells for a tolerogenic reset
Toleroxyl™ binds to GM-CSF receptors on concrete skin cells (Langerhans cells) triggering a key cell signaling pathway that controls immune responses – to keep these cells in a calm, tolerance-supporting state. Calmed LC secrete TGF-β, which helps reduce inflammatory signals (TNF-α, IL-8 and IL-6), promoting a healthy, non-inflamed skin environment. By reprogramming LC into a tolerogenic state, Toleroxyl™ helps reduce inflammation at its source and restore the skin’s natural immune balance. In other words, Toleroxyl™ does not force a new biology. It re-educates a depleted one.
Proven efficacy for hypersensitive skin
Toleroxyl™ has demonstrated to activate key tolerogenic pathways:
- Tolerogenic regulators restoration: RELB expression & SOX4 increase to reprogram the skin’s immune decision-making.
- Immunogenic markers resolution: CCR7, CD80, and CD86 are restored to physiological levels, preventing pollution-induced overreaction.
- Barrier reinforcement: Filaggrin, Loricrin, and Claudin-4 increase for structural
Clinical studies on volunteers with hyperreactive skin showed the efficacy of Toleroxyl™:
- Redness reduction and erythema
- Relief from stinging, itching, burning, and skin
- In vivo cytokine regulation: clinical reduction of pro-inflammatory markers (IL-8, TNF-α, and IL-6)
Toleroxyl™ opens new possibilities for cosmetic formulators seeking advanced concepts for sensitive, hyperreactive and urban skin care. Its mechanism supports multiple cosmetic territories, including:
- Tolerance-training formulations for sensitive
- Anti-redness serums and
- Anti-pollution daily care and suncare
- Skin comfort-restoring and barrier-support
- Recovery products for overstimulated
- Skin-balancing formulas for urban
With Toleroxyl™, Vytrus Biotech introduces a new cosmetic category designed for the era of hyperreactive urban skin. By combining plant biotechnology, recombinant protein science and a novel tolerogenic mechanism, the company offers formulators a new way to address sensitive skin: not by masking the signal, but by helping the skin relearn tolerance. Toleroxyl™ – Re-educating urban skin represents a new step in Vytrus’ mission to transform plant biotechnology into high-performance, sustainable and scientifically advanced cosmetic solutions.
https://www.vytrus.com/natural-active/toleroxyl
